Mortality in association with antipsychotic medication use and clinical outcomes among geriatric psychiatry outpatients with COVID-19

• DOI: 10.1371/journal.pone.0258916
• Publication Date: 2021-10-21T18:10:28Z
• Authors: Bienvenida Austria; Rehana Haque; Sukriti Mittal; Jamie Scott; Aninditha Vengassery; Daniel Maltz; Wentian Li; Blaine Greenwald; Yun Freudenberg-Hua
• Keywords: Geriatric psychiatry; 2019-20 coronavirus outbreak; Association (psychology)

Objectives Older adults are particularly vulnerable to the negative consequences of antipsychotic exposure and disproportionally affected by higher mortality from coronavirus disease 2019 (COVID-19). Our goal was determine whether concurrent medication use associated with increased COVID-19 in older patients preexisting behavioral health problems. We also report on findings post-COVID follow-ups. Design Retrospective observational study. Participants Outpatients at a geriatric psychiatric clinic New York City. Measurements Demographic clinical data including medication, diagnosis Clinical Global Impression Severity (CGI-S) scales outpatients who had between February 28 th October 1 st 2020 were extracted electronic records (EHR) hospital. Results A total 56 diagnosed (mean age 76 years; median 75 years) 13 (23.2%) died. found an risk for prescribed least one time infection (Fisher’s exact test P = 0.009, OR 11.1, 95% confidence interval: 1.4–96.0). This result remains significant after adjusting age, gender, housing context dementia (Logistic regression 0.035, Beta 2.4). Furthermore, we that most survived (88.4%) recovered pre-COVID baseline terms symptoms. Comparison pre- assessments CGI-S 33 not significantly different. Conclusion observed antipsychotics receiving services. The majority our appeared return their function. More precise estimates treatment other underlying factors will come larger datasets meta-analyses.